All In Biotech

Drug Trial Radar · NCT07029568

A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy People

A First in Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Target Engagement of Single and Multiple Oral Administrations of NNC0705-0001 in Healthy Adults

Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

116

Actual

Start

Jun 13, 2025

Primary completion

Nov 4, 2025

Study completion Dec 10, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jun 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is testing a new study medicine (called NNC0705-0001), as a potential medicine to treat chronic systemic inflammation, which is known for increasing the risk of developing cardiometabolic diseases. The aim of this study is to see if the study medicine is safe, how it works in our body, and what our body does to the study medicine. The participant will either get NNC0705-0001 or placebo (a "dummy medicine" without the active ingredient). Which treatment the participant gets is decided by chance. The study consists of 3 parts: PART A - single ascending dose (SAD); PART B - multiple ascending doses (MAD) and PART C - food effect (FE) on the pharmacokinetic (PK) properties of NNC0705-0001 and will last about 35 days (PART A) and 41 days (PART B and C).

Conditions

  • Healthy Volunteers
  • Chronic Kidney Disease

Interventions

  • NNC0705-0001Drug

    NNC0705-0001 will be administered orally.

  • PlaceboDrug

    Placebo matching NNC0705-0001 will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PART A: Number of treatment emergent adverse events (TEAE)Time frame: From time of dosing (day 1) to end of study (day 7)
  2. PART B: Number of TEAEsTime frame: From time of dosing (day 1) to end of study (day 13)
  3. AUC, SD; the area under the NNC0705-0001 plasma concentration-time curve after a single doseTime frame: From pre-dose (day 1 or day 8) to day 2 or day 9

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON - location Groningen

    Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.